Legal
Seventh Circuit Frees 2 ComEd Execs, Orders New Trial
The Seventh Circuit Court of Appeals ordered two former Commonwealth Edison executives released from federal prison hours after oral arguments on the FCPA's…
Latest — Page 19
Deals
Sold for $1.55B: Daiichi Sankyo's OTC Unit Goes to Suntory
Daiichi Sankyo sold its consumer health unit to Suntory Holdings for 246.5 billion yen, roughly $1.55 billion, in a staged transfer that kicks off this June…
Deals
Biogen Paid $5.6B for Apellis; Filing Confirms Deal Terms
Biogen paid $5.6B for Apellis, and a new SEC filing confirmed the deal details CEO Chris Viehbacher has been engineering: a company that doesn't grow on…
Deals
Bain Built $300M Beeline Medicines on 5 BMS Autoimmune Programs
Bain Capital put $300 million into Beeline Medicines at launch, licensing five autoimmune programs from Bristol Myers Squibb to build its next specialty…
FDA
FDA Cleared Foundayo With 3 Postmarketing Safety Study Requirements
FDA cleared Foundayo, Eli Lilly's oral GLP-1 pill for obesity, on April 1, but the approval letter lists three postmarketing requirements tied to what the…
Legal
Cleared: Judge Hoyt Acquits Rovirosa in FCPA's 4th Post-Trial Win
Judge Kenneth Hoyt of the U.S. District Court for the Southern District of Texas dismissed the FCPA indictment against Ramon Alexandro Rovirosa Martinez…
Legal
Treasury Filed First GENIUS Act Rule on $10B Stablecoin State Oversight
Treasury filed its first proposed rule under the GENIUS Act, 12 C.F.R. Parts 1520–1521, setting the standard that determines whether a stablecoin issuer…
FDA
FDA Cleared Filspari for FSGS; Travere Eyes $3B U.S. Peak
FDA cleared Filspari for focal segmental glomerulosclerosis on Monday, handing Travere Therapeutics a fresh shot at what it values as a more than $3 billion…
FDA
Doubles PDAC Survival: Revolution Jumps 40% on Daraxonrasib Phase 3 Data
Revolution Medicines shares jumped to $134.80 Monday, up nearly 40%, after daraxonrasib delivered overall survival of 13.2 months in metastatic pancreatic…
FDA
FDA Cleared Filspari for FSGS Despite Phase 3 Fail, Opening $2B Market
FDA cleared Filspari for focal segmental glomerulosclerosis on Monday, making Travere Therapeutics' endothelin blocker the first and only approved drug for…
Deals
Alamar Biosciences Files $159M IPO on 196% Revenue Growth
Alamar Biosciences wants $159 million from public markets, pricing 9.4 million shares at $15 to $17 apiece for a Nasdaq listing under "ALMR.
Legal
Filed: DOJ Moves to Block Rovirosa Release Before Hoyt's Dismissal
The DOJ asked U.S. District Court Judge Kenneth Hoyt in the Southern District of Texas to stay his forthcoming dismissal order in the foreign bribery…
FDA
IDEAYA Files FDA: Darovasertib Doubles PFS to 6.9 Months
Darovasertib, IDEAYA Biosciences and Servier's PKC inhibitor for metastatic uveal melanoma, more than doubled median progression-free survival in its Phase…
FDA
Ideaya Eye Cancer Drug Hits Phase 3, Files Accelerated NDA
Ideaya Biosciences cleared its own late-stage success benchmark for a rare eye cancer drug, and the company now plans to file for accelerated approval with FDA.
Deals
Click Therapeutics Cut More Than a Quarter of Staff After Series D
Click Therapeutics raised Series D funding, then cut more than a quarter of its workforce shortly after.
